Stock-research Ratings: Navidea Biopharmaceuticals, Inc (NAVB), First Industrial Realty Trust, Inc. (FR)

Navidea Biopharmaceuticals, Inc (NYSE:NAVB) tinted gains of +0.37% (0 points) to US$0.13. The volume of 0.19 Million shares climbed down over an trading activity of 558.59 Million shares. EPS ratio determined by looking at last 12 month figures is -0.12. Over the same time span, the stock marked US$0.41 as its best level and the lowest price reached was US$0.1. The corporation has a market cap of US$21.8 Million.

Navidea Biopharmaceuticals, Inc (NYSE:NAVB)’s earnings per share has been growing at a 22 percent rate over the past 5 year when average revenue increase was noted as 87.2 percent. The return on equity ratio or ROE stands at -355.9 percent while most common profitability ratio return on investment (ROI) was -101.6 percent. The company’s institutional ownership is monitored at 5.4 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 94.6 percent gross margin.

First Industrial Realty Trust, Inc. (NYSE:FR) is worth US$4.39 Billion and has recently risen 0.37% to US$34.89. The latest exchange of 0.49 Million shares is below its average trading activity of 716.69 Million shares. The day began at US$34.82 but the price moved to US$34.64 at one point during the trading and finally capitulating to a session high of US$34.94. The stock tapped a 52-week high of US$35.08 while the mean 12-month price target for the shares is US$36.

Currently, the stock carries a price to earnings ratio of 26.63, a price to book ratio of 2.67, and a price to sales ratio of 10.87. For the past 5 years, the company’s revenue has grown 4.9%, while the company’s earnings per share has grown 76.4%. With an institutional ownership near 95.2%, it carries an earnings per share ratio of 1.31.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 2 brokerage firms polled by Factset Research. At present, 5 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 2 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.33.